Breast cancer and the renin-angiotensin system (RAS): Therapeutic approaches and related metabolic diseases

Flávia Sardela de Miranda, João Pedro Tôrres Guimarães, Kalhara R. Menikdiwela, Brennan Mabry, Rabin Dhakal, Rakhshanda layeequr Rahman, Hanna Moussa, Naima Moustaid-Moussa

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The Renin-Angiotensin System (RAS) is classically recognized for regulating blood pressure and fluid balance. Recently, this role has extended to other areas including inflammation, obesity, diabetes, as well as breast cancer. RAS components are expressed in normal and cancerous breast tissues, and downregulation of RAS inhibits metastasis, proliferation, angiogenesis, and desmoplasia in the tumor microenvironment. Therefore, RAS inhibitors (Angiotensin receptor blockers, ARBs, or angiotensin converting enzyme inhibitors, ACE-I) may be beneficial as preventive adjuvant therapies to thwart breast cancer development and improve outcomes, respectively. Given the beneficial effects of RAS inhibitors in metabolic diseases, which often co-exist in breast cancer patients, combining RAS inhibitors with other breast cancer therapies may enhance the effectiveness of current treatments. This review scrutinizes above associations, to advance our understanding of the role of RAS in breast cancer and its potential for repurposing of RAS inhibitors to improve the therapeutic approach for breast cancer patients.

Original languageEnglish
Article number111245
JournalMolecular and Cellular Endocrinology
StatePublished - May 15 2021


  • Breast cancer
  • Cancer therapy
  • Renin-angiotensin system


Dive into the research topics of 'Breast cancer and the renin-angiotensin system (RAS): Therapeutic approaches and related metabolic diseases'. Together they form a unique fingerprint.

Cite this